What Leqembi treats
Leqembi (lecanemab-irmb) is an FDA-approved disease-modifying therapy for Alzheimer’s disease, specifically for patients with mild cognitive impairment (MCI) or mild dementia stage of Alzheimer’s, confirmed to have amyloid pathology. Leqembi works by targeting and reducing amyloid-beta plaques in the brain—a hallmark of Alzheimer’s—potentially slowing the progression of the disease.
Benefits of Leqembi
Clinical trials of Leqembi have shown:
- Slower cognitive and functional decline compared to placebo
- Reduced amyloid-beta plaque levels in the brain
- Potential improvement in quality of life and extended independence in early-stage patients
While not a cure, Leqembi represents a meaningful step toward modifying the underlying disease process.
Possible Side Effects of Leqembi
Leqembi is generally well-tolerated, but potential side effects include:
- Infusion-related reactions (chills, nausea, dizziness)
- ARIA-E and ARIA-H (Amyloid-Related Imaging Abnormalities—edema or hemorrhage seen on MRI)
- Headache
- Confusion or vision changes in rare cases
Patients receiving Leqembi require MRI monitoring throughout treatment and should be screened for APOE4 status, as it may increase the risk of ARIA.
How infusion works at Prime
Leqembi is administered at our infusion centers across New York and Atlanta. Our dedicated care team coordinates every step of your treatment with your prescribing physician.
Getting started
Patients: if you have a referral for Leqembi, send us an inquiry using the form below and our care team will take it from there. Physicians: referring a patient to Prime Infusions is simple — just complete and fax or email the referral form above.
Ready to start?
For a medical emergency, call 911.
Our Infusion Centers
FAQ
Frequently asked questions
How Does Leqembi Work?
Leqembi is a monoclonal antibody that binds to soluble and insoluble forms of amyloid-beta, helping the body clear these harmful protein deposits from the brain. Accumulation of amyloid-beta is believed to disrupt communication between neurons and drive cognitive decline. By reducing this burden, Leqembi offers a targeted approach to slow the progression of Alzheimer’s in its early stages. It is administered via intravenous infusion every two weeks.
Who is Leqembi For?
Leqembi is indicated for:
- Adults with early Alzheimer’s disease, including mild cognitive impairment (MCI) and mild dementia
- Patients who have confirmed amyloid-beta buildup via PET scan or CSF biomarker testing
It is not intended for late-stage Alzheimer’s or patients without biomarker-confirmed disease.